Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo

This article was originally published in The Tan Sheet

Executive Summary

Ted Borgel named VP-quality & compliance, private labeler announces Feb. 7. Borgel will be responsible "for all quality assurance and regulatory compliance functions and will serve as a member of the Corporate Planning Team," firm says. Borgel brings more than 35 years of experience in senior management roles at companies such as Eli Lilly, Alcon Labs and Bausch & Lomb and faces the challenge of cleaning up Perrigo's quality control program following unfavorable FDA inspection of firm's Allegan, Mich. facility in August (1"The Tan Sheet" Sept. 11, 2000, p. 13)

You may also be interested in...



Perrigo Extended-Release Acetaminophen Launch Delayed By QC Issues

Perrigo has postponed its plans to market private label extended-release acetaminophen until it can resolve quality control issues outlined in a recent FDA warning letter.

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS092181

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel